Introducing finger prick test to advance cancer detection
New York: A finger prick test for cancer may soon be possible as researchers have developed a new technology to detect disease biomarkers in the form of nucleic acids, the building blocks of all living organisms.
"We envision this as a potential first-line, noninvasive diagnostic to detect anything from cancer to the Ebola virus," said lead author of the study Adam Hall, assistant professor of biomedical engineering at Wake Forest Baptist Medical Centre in North Carolina, the US.
"Although we are certainly at the early stages of the technology, eventually we could perform the test using a few drops of blood from a simple finger prick," Hall noted.
Nucleic acids consist of chains or sequences of bases stretching from just a few to millions of elements long.
The exact order in which these bases are found, even over short distances, is strongly tied to their functions, and therefore can be used as direct indicators of what is going on inside cells and tissue.
For example, one family of these nucleic acids known as microRNAs are only about 20 bases long, but can signal a wide range of diseases, including cancer.
"Scientists have studied microRNA biomarkers for years but one problem has been accurate detection because they are so short, many technologies have real difficulty identifying them," Hall said.
In the new technique, nanotechnology is used to determine whether a specific target nucleic acid sequence exists within a mixture and to quantify it if it does through a simple electronic signature.
"If the sequence you are looking for is there, it forms a double helix with a probe we provide and you see a clear signal. If the sequence isn't there, then there is not any signal," Hall said.
"By simply counting the number of signals you can determine how much of the target is around," Hall said.
In this study, published online in the journal Nano Letters, the team first demonstrated that the technology could effectively identify a specific sequence among a background of competing nucleic acids and then applied their technique to one particular microRNA (mi-R155) known to indicate lung cancer in humans.
"We envision this as a potential first-line, noninvasive diagnostic to detect anything from cancer to the Ebola virus," said lead author of the study Adam Hall, assistant professor of biomedical engineering at Wake Forest Baptist Medical Centre in North Carolina, the US.
"Although we are certainly at the early stages of the technology, eventually we could perform the test using a few drops of blood from a simple finger prick," Hall noted.
Nucleic acids consist of chains or sequences of bases stretching from just a few to millions of elements long.
The exact order in which these bases are found, even over short distances, is strongly tied to their functions, and therefore can be used as direct indicators of what is going on inside cells and tissue.
For example, one family of these nucleic acids known as microRNAs are only about 20 bases long, but can signal a wide range of diseases, including cancer.
"Scientists have studied microRNA biomarkers for years but one problem has been accurate detection because they are so short, many technologies have real difficulty identifying them," Hall said.
In the new technique, nanotechnology is used to determine whether a specific target nucleic acid sequence exists within a mixture and to quantify it if it does through a simple electronic signature.
"If the sequence you are looking for is there, it forms a double helix with a probe we provide and you see a clear signal. If the sequence isn't there, then there is not any signal," Hall said.
"By simply counting the number of signals you can determine how much of the target is around," Hall said.
In this study, published online in the journal Nano Letters, the team first demonstrated that the technology could effectively identify a specific sequence among a background of competing nucleic acids and then applied their technique to one particular microRNA (mi-R155) known to indicate lung cancer in humans.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd